Hot Investor Mandate: Large Holding Company With Multiple Investment Vehicles Seeks to Invest in Software-Based Digital Health Companies Targeting the USA Market

9 Feb

An investment group with multiple investment vehicles manages approx. $1.5B targeted on healthcare and life science under management. The firm launched a new vehicle in 2020 to invest in digital health technologies. The group will invest $1-2M, mainly in seed-series A companies developing software-based digital technologies. While the firm will invest globally, they are looking for companies targeting the US market.

The firm is interested in software-based digital health companies. The group will not invest in wearables or smart devices. The firm invests primarily in B2B or B2B2C companies, and looks for technologies that have clear cost saving or revenue generating aspect for clients.

The firm is a very active investor, leveraging their network and broad-cross sector activity to help their portfolio companies. The group is looking for companies that, at minimum, have a viable understanding of the US healthcare market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC & Growth Equity Firm Actively Seeks Devices, Diagnostics, and Digital Health, Investing Up to $30M Over the Company’s Life Cycle

9 Feb

A venture capital and growth equity firm providing expertise and funding to companies with global ambitions in healthcare technologies. The firm is headquartered in Western Europe with teams in the US. The firm is currently making investments from a relatively new fund closed in 2021. The firm prefers to be the lead investor and possibly co-lead, seeking to allocate US$20-30 million (in equity) per company through subsequent rounds of investment. The firm invests in growth-stage companies that are based in the US and Europe and is actively seeking new investment opportunities.

The firm invests in medical devices, digital health, and diagnostic technologies. The firm focuses on companies that can address a specific unmet medical need or deliver considerable improvements to care delivery. Innovative healthcare technologies with a therapeutic focus are of high interest. The firm is opportunistic in terms of subsectors and indications and seeks companies that are in commercial ramp-up.

The firm requests a board seat in each portfolio company and generally holds a significant minority stake. Companies seeking investment should be led by a strong and experienced management team and have the support of technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe-Based Investment Firm Seeks Global Investments in Therapeutics and Diagnostics Focusing on Age-Related Diseases

9 Feb

An investment firm headquartered in Western Europe, with additional offices in USA and Asia, has a fund dedicated to investing in 25-28 companies in Seed to Series A financing rounds. The firm seeks to invest in innovations directly related to the prevention of age-associated diseases, extension of a healthy lifespan, and improving the performance of humans and animals. The firm’s initial check size can range from $500K – 1.5M, and the firm is open to global opportunities.

Within life sciences, the firm is most interested in therapeutics and diagnostics companies, and will also consider digital health. Medical devices with traditional regulatory pathways are generally out of scope for the firm. Within these sectors, interest areas can include gene therapy, telomere attrition, proteostasis, regenerative medicine, personalized diagnostics/biomarkers, preventative therapies, cognitive enhancement, and more. That said, the firm has no strong interest in particular technologies and is open to all modalities. The firm is also opportunistic in terms of stage of development.

The firm seeks companies with strong, protectable IP with clear origins and ownership, backed by a diverse team with a strong track record and technologies with validated proof of concept. The firm has a 3-step due diligence process which includes: (1) initial review, (2) additional review – where the firm looks more closely into main differentiating factors of the company (IP, business model, etc.), and (3) final review. The firm is open to leading, co-leading, or co-investing, and has a strong co-investment and syndication network of likeminded investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm With Global Offices Supports Life Science Companies on Funding Clinical Trials, Most Focused on Therapeutics But Open to Other Sectors

9 Feb

A firm headquartered in Asia with offices in US and Europe invests specifically in companies that are raising funds to carry out clinical trials which can be performed, totally or in part, in an affiliated network of sites located in Europe and Asia. The firm typically invests alongside lead investors with a track record in biotech or medtech, and usually funds a large fraction of clinical trial costs. The firm can fund up to 10-15 trials per year. The size of investments is flexible, scaled to the clinical trial requirements, and will mostly range from 1 to 6 million USD/EUR. Investments made by the firm will fund work performed by a top-tier FDA-inspected network of sites offering clinical studies and CRO services to major pharma companies.

Although focused primarily on therapeutics, the firm also consider diagnostics, medical devices, and digital health companies. The firm is generally indication-agnostic but has a keen interest in fields such as diabetes, pulmonology, ophthalmology and some cancers. The firm is primarily interested in companies running Phase I / Phase II clinical trials or equivalent.

The firm looks to act as a co-investor and will typically not require a board seat. The firm will more often invest when there is a lead investor on board. The firm has no specific requirements for the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

NEW! Global Partnering Campaign & Roadshow Preparation Entrepreneurial Education Series

2 Feb

By Caitlin Dolegowski, Marketing Manager, LSN

2023 is an important year for LSN’s Entrepreneurial Education programs. We have devised 16+ focused and very practical 1-hour classes that address genuine issues facing startups. At Digital RESI March Life Science Nation will be offering an educational track for the first time, consisting of 6 focused classes over 3 days and covering topics:

It All Starts with The Story

Tuesday, March 14, 11 AM EDT

The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company’s unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch, or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook.

First-Time CEOs: Avoiding Pitfalls

Tuesday, March 14, 12 PM EDT

This session will cover some of the most common pitfalls that catch first-time and serial entrepreneurs off guard. From false premise and being tentative to surrounding yourself with executives that do not have augmentative and complimentary skillsets, there are many things that can slow the growth of your early-stage life science entity. By learning how to avoid these issues and not run yourself over, your chances of making it to the market will increase greatly.

Tagline & Elevator Pitch

Wednesday, March 15, 11 AM EDT

Distilling your company identity into a 5–7-word tagline and then expanding upon that in a 5-7 sentence elevator pitch is one of the most fundamental business development skills that early-stage entrepreneurs must master when launching global partnering campaigns. Join us to learn how to develop a compelling tagline and convincing elevator pitch to grip the attention of your target investors and licensing partners.

Executive Summary & Tear Sheet

Wednesday, March 15, 12 PM EDT

This session will cover how to develop a compelling 2-page executive summary and 1-page tear sheet, two of the most important materials to have at the ready for interested investors and licensing partners. While the executive summary covers a deeper dive into your company’s history, product, and management team, the tear sheet can be used to synthesize all of the most important elements of your company in 5-10 minutes (ideal for partners looking to skim through a document).

Pitch Deck & The 10 Myths of Fundraising

Thursday, March 16, 11 AM EDT

The pitch deck is the final piece of marketing collateral (having previously established your tagline, elevator pitch, executive summary, and tear sheet) that can help cogently tell your company’s unique story and highlight its key value points. As the pitch deck is one of the most requested materials by investors and licensing partners, this session will also cover the 10 myths of fundraising to help elucidate some common misconceptions when launching global campaigns.

Strategies for Successful Partnering

Thursday, March 16, 12 PM EDT

Take a deep dive into your outreach campaign. Learn more about our proven successful strategy and how to craft your messages from your initial outreach and each follow up message after that.

Additionally, this registration includes access to investor panels, pitch sessions and workshops live or recorded for $295. (No Partnering)

register-now-button

Digital RESI March 2023 Email Banner.(NEWtouse)

Digital RESI March Panel Line-up

2 Feb

By Love Chung, Investor Research Analyst, LSN

Love-headshot

The Redefining Early Stage Investment (RESI) conference series returns this March 14-16 in a fully virtual format. Through a carefully curated agenda including Innovator’s Pitch Challenges, educational workshops, panels, and more, entrepreneurs will be able to connect with investors and strategic partners who best match their product and stage of development. The panels will continue to feature investors, industry experts, and seasoned entrepreneurs providing valuable insight to our conference attendees.

Digital RESI March will be bringing on investor panels (featuring investors representing groups such as Angels, Corporate Venture Capital, Family Offices) that entail key topics of life science such as Therapeutics, Chronic Disease Management, Impact Investing, Health Systems, and more. Click here to see the agenda of the upcoming conference. To save $200 on Digital RESI, make sure to complete the early bird registration by February 10th!

Digital-RESI-March-Panel-Agenda

Digital RESI March 2023 Email Banner.(NEWtouse)

I Asked an AI Robot to Tell Me About Entrepreneurial Storytelling (I am not kidding)

2 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

I asked the Robot, Open AI, Chat GPT to write an article on why scientist entrepreneurs and fundraising CEOs need to get their stories straight and develop a compelling company narrative. Here is the very impressive result!

In today’s business world, it is not enough for scientist entrepreneurs and fundraising CEOs to simply have a great idea or product. In order to be successful, they must also have a clear and compelling narrative that effectively communicates the value of their work to potential investors and customers.

One of the key reasons that a strong narrative is so important is that it helps to differentiate a company or product from its competitors. In a crowded marketplace, it can be difficult to stand out and make a lasting impression on potential investors or customers. By having a clear and compelling story, a scientist entrepreneur or fundraising CEO can effectively communicate the unique value proposition of their product or idea, and why it is worth investing in.

Another important reason that a strong narrative is necessary is that it helps to build trust and credibility. When a scientist entrepreneur or fundraising CEO can clearly and effectively communicate the value of their work, it helps to instill confidence in potential investors and customers that the company or product is worth supporting. This is especially important when seeking funding or investment, as investors are more likely to put their money into a company or product that they believe in.

Finally, a strong narrative can also help to build a sense of community and engagement around a company or product. When people are able to connect with the story of a company or product, they are more likely to become invested in it and to want to support it. This can be especially beneficial for fundraising CEOs and scientist entrepreneurs, as it can help to generate interest and enthusiasm among potential investors and customers.

In conclusion, scientist entrepreneurs and fundraising CEOs need to get their story straight and develop a compelling narrative in order to effectively communicate the value of their work and stand out in a crowded marketplace. By doing so, they can build trust, credibility and a sense of community around their company or product and increase the chances of success.

Click on the podcast/class below to hear my take on the question above.